SGHT guidance is weak and hopefully a reflection of them losing share.
"Sight Sciences projects revenue for full year 2024 to range from approximately $81.0 million to $85.0 million, representing a range of 0% to 5% growth compared to 2023. The Company expects double-digit revenue growth in the second half of 2024 versus the comparable periods in the prior year as it regains commercial momentum and expands utilization and its customer base."
Nova Eye Medical (EYE) Discussion, page-2412
-
- There are more pages in this discussion • 767 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.34M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 21.0¢ | $95.62K | 444.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 52740 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 73205 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| EYE (ASX) Chart |